StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.84+0.01 (+0.97%)

Close on Nov 17, 2026Market cap $13.95MP/E –Yield –

Marker Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Marker Therapeutics's price to sales ratio was 4.8× on Jul 31, 2026, against 2.8× a year earlier. Over the last 4 years it ranged from 1.7× to 407.3×, with a median of 6.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 20264.8×−0.5
2025Dec 31, 20255.3×+0.2
2024Dec 31, 20245.1×−10.9
2023Dec 29, 202316.1×−243.5
2021Apr 30, 2021259.6×−147.7
2020Mar 31, 2020407.3×+253.8
2018Apr 30, 2018153.4×–

More Marker Therapeutics figures

See a number that looks wrong?